John M. Lambert

TL;DR: In vitro and in vivo efficacy, pharmacokinetics, and toxicity of trastuzumab-maytansinoid (microtubule-depolymerizing agents) conjugates using disulfide and thioether linkers are determined andtrastuzuab-MCC-DM1 shows greater activity compared with nonconjugated trastumab while maintaining selectivity for HER2-overexpressing tumor cells.

TL;DR: A cytotoxic agent comprising one or more maytansinoids linked to a cell binding agent, and a pharmaceutically acceptable carrier, diluent or excipient is defined in this article.

TL;DR: Resurfaced N901 and anti-B4 antibodies had apparent affinities for their cell surface ligands that were identical to those of their respective parent murine antibodies, suggesting that, despite the differences in the surfaces of mouse and human Fv regions, it is possible to substitute one for the other while retaining full antigen binding affinity.

TL;DR: In 2013, T-DM1 received FDA approval for the treatment of patients with HER2-positive metastatic breast cancer who had previously received trastuzumab and a taxane, separately or in combination, the first ADC to receive full approval based on a randomized study.

TL;DR: C242-DM1 represents a new generation of immunoconjugates that may yet fulfill the promise of effective cancer therapy through antibody targeting of cytotoxic agents.